Screener
Emergent Biosolutions EBS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
FAQ
- What is Emergent Biosolutions's total current liabilities?
- Emergent Biosolutions (EBS) reported total current liabilities of $122.8M in Q2 2026.
- How has Emergent Biosolutions's total current liabilities changed year-over-year?
- Emergent Biosolutions's total current liabilities decreased by 3.4% year-over-year, from $127.1M to $122.8M.
- What is the long-term trend for Emergent Biosolutions's total current liabilities?
- Over 5 years (2020 to 2025), Emergent Biosolutions's total current liabilities has grown at a -19.2% compound annual growth rate (CAGR), from $384.5M to $132.2M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Emergent Biosolutions's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude